WHAT IS CLAIMED IS:

1. A method of regulating the production of recombinant adeno-associated virus (rAAV) vector particles, the method comprising:

a) introducing into a cell:

(i). an rAAV comprising a gene of interest; and

(ii). a nucleic acid encoding a fusion protein, wherein the fusion protein comprises an AAV protein, and a degradation ligand-dependent degradation domain,

b) culturing the cell under conditions suitable for producing the rAAV vector particles; and

c) contacting the cell with a degradation ligand, wherein the degradation ligand binds to the degradation domain to regulate the expression of the AAV protein and thereby regulate the production of rAAV vector particles.

2. The method of claim 1, wherein the nucleic acid encoding the fusion protein further encodes a linker, operably linking the AAV protein to the degradation ligand-dependent degradation domain.

3. The method of claim 1 or claim 2, wherein the AAV protein is selected from the group consisting of Cap, Rep, and Helper proteins.

4. The method of any one of claims 1-3, wherein the degradation ligand-dependent degradation domain:

(a) is derived from FKBP;

(b) is dihydrofolate reductase (DHFR); or

(c) is an auxin induced degradation domain.

5. The method of claim 3, wherein the Rep protein is Rep78, Rep68, Rep52, or Rep40 protein.

6. The method of any one of claims 3-5, wherein:

(a) the degradation ligand-dependent degradation domain is fused to the C-terminal end

of the Rep protein; or

(b) the degradation ligand-dependent degradation domain is fused to the N-terminal end of the Rep protein.

7. The method of any one of claims 1-6, comprising introducing into the cell a nucleic acid encoding a Cap protein, wherein:

(a) the nucleic acid encoding the fusion protein and the nucleic acid encoding a Cap protein, are introduced into the cell using the same plasmid; or

(b) the nucleic acid encoding the fusion protein and the nucleic acid encoding a Cap protein, are introduced into the cell using separate plasmids.

8. The method of any one of claims 1-7, wherein the rep, cap, or helper genes are under the control of a regulatory element.

9. The method of claim 8, wherein said regulatory element comprises a Tet response binding element.

10. The method of claim 1, wherein the animal cell is a mammalian cell.

11. The method of any one of claims 1-10, wherein:

(a) two or more different AAV proteins are independently fused to degradation ligand-dependent degradation domains; or

(b) each different AAV protein is independently fused to a different degradation ligand-dependent degradation domain.

12. A rAAV producing cell, wherein the cell comprises a nucleic acid encoding a fusion protein comprising an AAV protein, and a degradation ligand-dependent degradation domain.

13. The rAAV producing cell of claim 12, wherein the nucleic acid encoding a fusion protein comprises the AAV protein, a linker, and a degradation ligand-dependent degradation domain.

14. The rAAV producing cell of claim 12 or claim 13, wherein the AAV protein is selected

from the group consisting of Rep, Cap, and Helper proteins.

15. The rAAV producing cell of any one of claims 12-14, wherein the degradation ligand-dependent degradation domain :

(a) is derived from FKBP;

(b) is dihydrofolate reductase (DHFR); or

(c) is an auxin induced degradation domain.

16. The rAAV producing cell of 12, wherein the animal cell is a mammalian cell.

17. The rAAV producing cell of any one of claims 14-16, wherein:

(a) the degradation ligand-dependent degradation domain is fused via the linker to the C-terminal end of the Rep protein; or

(b) the cell is a mammalian cell and the degradation ligand-dependent degradation domain is fused via the linker to the N- terminal end of the Rep protein.

18. The rAAV producing cell of claim 16 or claim 17, further comprising introducing into the cell a nucleic acid encoding a Cap protein, wherein:

(a) the cell is a mammalian cell and the nucleic acid encoding the fusion protein and the nucleic acid encoding a Cap protein are introduced into the cell using the same plasmid; or

(b) the cell is a mammalian cell and the nucleic acid encoding the fusion protein and the nucleic acid encoding a Cap protein are introduced into the cell using separate plasmids.

19. The rAAV producing cell of any one of claims 16-18, wherein the cell is a mammalian cell and the rep, cap, or helper genes are under the control of a regulatory element.

20. The rAAV producing cell of any one of claims 12-19 wherein:

(a) two or more different AAV proteins are independently fused to degradation ligand-dependent degradation domains; or

(b) each different AAV protein is independently fused to a different degradation ligand-dependent degradation domain.